# A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma

> **NCT00925314** · PHASE2 · UNKNOWN · sponsor: **Cosmo Bioscience** · enrollment: 20 (estimated)

## Conditions studied

- Stage IIIB Skin Melanoma
- Stage IIIC Skin Melanoma

## Interventions

- **BIOLOGICAL:** CB-10-01 (Transgenic Lymphocyte Immunization)

## Key facts

- **NCT ID:** NCT00925314
- **Lead sponsor:** Cosmo Bioscience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-06
- **Primary completion:** 2011-07
- **Final completion:** 2014-07
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2012-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00925314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00925314, "A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00925314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*